ERBB2 and ovarian carcinoma: In the new drug target discovery, it was found that ERBB2 is activated in patients with ovarian cancer, and for BMS-, pirotinib, allitinib, poziotinib, erlotinib, sapitinib, osimertinib, lapatinib, nordihydroguaiaretic acid, and afatinib (activation score > 0.7), which can inhibit ERBB2, were found among upstream regulators found only in the integrated analysis.